2022年度実績

2022年度業績

 

【英文論文】

 

Imaji M, Fujimoto D, Sato Y, Sakata Y, Oya Y, Tamiya M, Suzuki H, Ikeda H, Kijima T, Matsumoto H, Kanazu M, Hino A, Inaba M, Tsukita Y, Arai D, Maruyama H, Hara S, Tsumura S, Kobe H, Sumikawa H, Sakata S, Yamamoto N. Safety and efficacy of osimertinib rechallenge or continuation after pneumonitis: A multicentre retrospective cohort study.

Eur J Cancer. 2023 Jan;179:15-24.

 

Tanaka K, Chamoto K, Saeki S, Hatae R, Ikematsu Y, Sakai K, Ando N, Sonomura K, Kojima S, Taketsuna M, Kim YH, Yoshida H, Ozasa H, Sakamori Y, Hirano T, Matsuda F, Hirai T, Nishio K, Sakagami T, Fukushima M, Nakanishi Y, Honjo T, Okamoto I. Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer.

Sci Transl Med. 2022 Dec 14;14(675):eabq0021.

 

Yamakawa M, Nakane S, Ihara E, Tawara N, Ikeda H, Igarashi Y, Komohara Y, Takamatsu K, Ikeda T, Tomita Y, Murai S, Ando Y, Mukaino A, Ogawa Y, Ueda M. A novel murine model of autoimmune dysautonomia by α3 nicotinic AChR immunization.

Front Neurosci. 2022 Nov 23;16:1006923.

 

Jodai Y, Hamada S, Yamada M, Masuda Y, Anai M, Jodai T, Tomita Y, Saeki S, Ichiyasu H, Sakagami T. Primary lung sebaceous carcinoma successfully treated with radiotherapy and pembrolizumab: a case report.

Thorac Cancer. 2023 Jan;14(3):331-335.

 

Furukawa T, Akaike K, Iyama S, Masunaga A, Tomita Y, Saeki S, Ichiyasu H, Sakagami T. Interstitial Lung Disease in Adulthood Associated with Surfactant Protein C Gene Mutation in a Patient with a History of Lipoid Pneumonia in Infancy: A Case Report.

Intern Med. 2023 Jan 15. doi: 10.2169/internalmedicine.0980-22.

 

Imamura K, Tomita Y, Sato R, Ikeda T, Iyama S, Jodai T, Takahashi M, Takaki A, Akaike K, Hamada S, Sakata S, Saruwatari K, Saeki S, Ikeda K, Suzuki M, Sakagami T. Clinical Implications and Molecular Characterization of Drebrin-Positive, Tumor-Infiltrating Exhausted T Cells in Lung Cancer.

Int J Mol Sci. 2022 Nov 8;23(22):13723.

 

Akaike K, Saruwatari K, Matsushima R, Fujino K, Morinaga J, Oda S, Takahashi H, Shiraishi S, Okabayashi H, Hamada S, Tomita Y, Masunaga A, Saeki S, Ikeda K, Ichiyasu H, Suzuki M, Sakagami T. Clinical impact of SUVmax of interstitial lesions in lung cancer patients with interstitial lung disease who underwent pulmonary resection.

J Thorac Dis. 2022 Oct;14(10):3801-3810.

 

Anai M, Yoshida C, Izumi H, Muramoto K, Saruwatari K, Tomita Y, Ichiyasu H, Sakagami T. Successful treatment with dupilumab for mucus plugs in severe asthma. Respirol Case Rep. 2022 Dec 15;11(1):e01074. doi: 10.1002/rcr2.1074.

 

Sato Y, Sumikawa H, Shibaki R, Morimoto T, Sakata Y, Oya Y, Tamiya M, Suzuki H, Matsumoto H, Yokoi T, Hashimoto K, Kobe H, Hino A, Inaba M, Tsukita Y, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Sakata S, Fujimoto D. Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Real-World Setting.

Chest. 2022 Nov;162(5):1188-1198.

 

Ikeda T and Tomita Y. Statistical concern regarding the relationship of change in mucus plug score with airflow over time.

Am J Respir Crit Care Med. 2022 Nov 15;206(10):1299.

 

Tomita Y, Goto Y, Sakata S, Imamura K, Minemura A, Oka K, Hayashi A, Jodai T, Akaike K, Anai M, Hamada S, Iyama S, Saruwatari K, Saeki S, Takahashi M, Ikeda T, Sakagami T. Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors.

OncoImmunology. 2022 May 27;11(1):2081010.

 

Hirotake Tsukamoto, Yoshihiro Komohara, Yusuke Tomita, Yuji Miura,Takanobu Motoshima, Kosuke Imamura, Toshiki Kimura, Tokunori Ikeda, Yukio Fujiwara, Hiromu Yano, Tomomi Kamba, Takuro Sakagami, Hiroyuki Oshiumi. Aging-associated and CD4 T cell-dependent ectopic CXCL13 activation predisposes to anti-PD-1 therapy-induced adverse events.

Proc Natl Acad Sci U S A. 2022. 119 (29) e2205378119.

 

Cao S, Zhang Y, Zhou Y, Rong W, Wang Y, Ling X, Zhang L, Li J, Tomita Y, Watanabe S, Nakada T, Seki N, Hida T, Dermime S, Zhong R, Zhong H. A nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer.

Transl Lung Cancer Res. 2022 Apr;11(4):607-616.

 

Matsubara E, Komohara Y, Esumi S, Shinchi Y, Ishizuka S, Mito R, Pan C, Yano H, Kobayashi D, Fujiwara Y, Ikeda K, Sakagami T, Suzuki M. SPP1 Derived from Macrophages Is Associated with a Worse Clinical Course and Chemo-Resistance in Lung Adenocarcinoma.

Cancers. 2022; 14(18):4374.

 

Aoki A, Saito A, Shima K, Kimura Y, Asakawa K, Ohashi R, Umezu H, Sakagami T, Moriyama H, Kikuchi T. Occupational Lung Disease Caused by Exposure to Polytetrafluoroethylene.

Intern Med. 2022 Dec 15;61(24):3713-3717.

 

Shinchi, Y., Ishizuka, S., Komohara, Y. et al. The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma.

Cancer Immunol Immunother 71, 2645–2661 (2022).

 

Sakata S, Otsubo K, Yoshida H, Ito K, Nakamura A, Teraoka S, Matsumoto N, Shiraishi Y, Haratani K, Tamiya M, Ikeda S, Miura S, Tanizaki J, Omori S, Yoshioka H, Hata A, Yamamoto N, Nakagawa K. Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L.

Cancer Sci. 2022;113:221-228.

 

Hirose M, Ishimaru Y, Sakata S, Sakagami T. Rapid Shrinkage of Retroperitoneal Lymphangioleiomyoma after Sirolimus Initiation.

Intern Med. 2022;61:2081-2082.

 

Fujimoto D, Akamatsu H, Morimoto T, Wakuda K, Sato Y, Kawa Y, Yokoyama T, Tamiya M, Hiraoka R, Shingu N, Ikeda H, Tamiya A, Kanazu M, Miyauchi E, Miura S, Yanai M, Yomota M, Morinaga R, Yokoi T, Hata A, Suzuki H, Matsumoto H, Sakata S, Furuya N, Harutani Y, Nakachi I, Otsuki A, Uematsu S, Hara S, Yokoo K, Sugimoto T, Yamamoto N. Histologic transformation of epidermal growth factor receptor-mutated lung cancer.

Eur J Cancer. 2022;166:41-50.

 

Hayashi H, Yonesaka K, Nakamura A, Fujimoto D, Azuma K, Sakata S, Tachihara M, Ikeda S, Yokoyama T, Hataji O, Yano Y, Hirano K, Daga H, Okada H, Chiba Y, Sakai K, Nishio K, Yamamoto N, Nakagawa K. Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L).

Lung Cancer. 2022;168:38-45.

 

Anai M, Saruwatari K, Ikeda T, Oda S, Tajima Y, Jodai T, Sakata S, Iyama S, Tomita Y, Saeki S, Ichiyasu H, Sakagami T. Clinical impact of cerebral infarction in patients with non-small cell lung cancer.

Int J Clin Oncol. 2022 May;27(5):863-870.

 

Moriyasu Anai, Chieko Yoshida, Kazutaka Ozono, Hirotsugu Furukawa, Yuko Ishimaru, Shinya Sakata, Koichi Saruwatari, Kei Muramoto, Yusuke Tomita, Sho Saeki, Hidenori Ichiyasu, and Takuro Sakagami.  Successful concomitant therapy with mepolizumab and dupilumab for atypical eosinophilic granulomatosis with polyangiitis.

Allergol Int. 2022 Apr;71(2):259-261.

 

Tamanoi D, Saruwatari K, Imamura K, Sato R, Jodai T, Hamada S, Tomita Y, Saeki S, Ueno S, Yonemura Y, Ichiyasu H, Sakagami T.

Pembrolizumab-related Immune Thrombocytopenia in a Patient with Lung Adenocarcinoma Treated by Radiotherapy: Potential Immune-related Adverse Event Elicited by Radiation Therapy.

Intern Med. 2022;61(11):1731-1734.

 

Shiraishi Y, Shimose T, Tsuchiya-Kawano Y, Ishii H, Daga H, Ito K, Saruwatari K, Okamoto I. Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain Metastases.

Cancer Manag Res. 2022;14:3449-3453.